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who suffered a VTE event and those that did not. Risk adjustment was done using 
propensity score matching (using the ProbChoiceTM algorithm) controlling for baseline 
demographic and clinical characteristics between patients with and without VTE. 
RESULTS: In patients who underwent hip fracture surgery (n = 104,952), 1.9% had 
post-operative VTE events during their initial hospitalization. Almost 69% (n = 1377) 
of these patients suffered deep vein thrombosis (DVT), 25% (n = 501) had a pulmo-
nary embolism (PE), and 6% (n = 119) had both DVT and PE. After multivariate 
adjustment for pre-speciﬁed covariates, mortality was almost 50% higher for patients 
with VTE compared to those without VTE. Differences in mortality rate were more 
pronounced for PE patients, whom the event was associated with almost two-fold. 
The VTE group was more likely to be re-hospitalized in one year (odds ratio: 1.44, p 
= 0.02). Bleeding was 2.26 times higher (p = 0.000). CONCLUSIONS: VTE events 
during initial hospitalization for hip fracture surgery increased the mortality, re-hos-
pitalization and bleeding compared with no VTE events.
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OBJECTIVES: To estimate re-hospitalization and bleeding rates during the 90 days 
after a venous thromboembolism (VTE) event in patients who underwent knee replace-
ment surgery and to compare the outcomes with patients who did not suffer 
VTE. METHODS: Based on 2005–2007 national Medicare claims, all patients who 
underwent knee replacement surgery were identiﬁed. The 90 days follow-up event rates 
for patients who had a VTE event during their initial hospitalization were calculated. 
Events were compared between patients who suffered a VTE event and those who did 
not. Risk adjustment was done using propensity score matching (using the ProbChoi-
ceTM algorithm) controlling for baseline demographic and clinical characteristics 
between patients with and without VTE. RESULTS: In patients who underwent total 
knee replacement surgery (n = 104,952), 1.9% had post-operative VTE events during 
their initial hospitalization. Almost 69% (n = 1377) of these patients had deep vein 
thrombosis (DVT), 25% (n = 501) had pulmonary embolism (PE), and 6% (n = 119) 
had both DVT and PE. The overall likelihood of mortality was four times higher for 
VTE patients versus those without VTE (1.35% vs. 0.35%). Patients with VTE during 
their initial hospitalization were more likely to be hospitalized in 90 days (compared to 
patients without an event during the same hospital stay (16.62% vs. 8.00%). In 90 days 
after the event, patients with VTE were more likely to have bleeding (10.17% vs. 
2.68%). CONCLUSIONS: VTE events during initial hospitalization for total knee 
replacement surgery increased the adverse events compared with no VTE events.
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OBJECTIVES: To estimate re-hospitalization and bleeding during the 30 days after a 
venous thromboembolism (VTE) event in patients following hip fracture surgery and 
to compare the outcomes with patients without VTE. METHODS: Based on 2005–
2007 national Medicare claims, all patients who underwent hip fracture surgery were 
identiﬁed. The 30 days follow-up event rates for patients who had a VTE event during 
their initial hospitalization were calculated. Events were compared between patients 
who suffered a VTE event and those who did not. Risk adjustment was done using 
propensity score matching controlling for baseline demographic and clinical charac-
teristics between patients with and without VTE. RESULTS: In patients who under-
went hip fracture surgery (n = 50,245), 1.5% had post-operative VTE during their 
initial hospitalization. Almost 77% (n = 573) of these patients had deep vein throm-
bosis (DVT), 20% (n = 141) had a pulmonary embolism (PE), and 3% (n = 34) had 
both DVT and PE. Patients with VTE during their initial hospitalization were more 
likely to be hospitalized in 30 days (compared to patients without an event during the 
same hospital stay (32% vs. 6.82%). In 30 days after the event, patients with VTE 
were more likely to have bleeding (10.65% vs. 0.68%). CONCLUSIONS: VTE events 
during initial hospitalization for hip fracture surgery patients increased the adverse 
events compared with no VTE events.
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OBJECTIVES: The aim of this study was to conduct a meta-analysis of randomized 
clinical trials (RCTs) to identify the effectiveness and safety of atorvastatina 
(20 mg–80 mg) against pravastatin, simvastatin and rosuvastatin. METHODS: A 
systematic review was performed including RCTs in primary and secondary preven-
tion where total cholesterol, LDL-C, HDL-C, major cardiovascular events, as well as 
adverse events frequency werw analyzed. RCTs were searched in March 2009 in 
Medline, EMBASE and the Cochrane Collaboration. Two independent reviewers 
identiﬁed the abstracts, selected the full articles, and extracted the data. Odds ratios 
(OR) and weighted means differences were calculated with 95% conﬁdence intervals 
(95%CI). Random effects models were employed in the Meta-analyses using RevMan 
v.5.0 software. RESULTS: From 7539 studies, 66 RCT were selected. Atorvastatin 
showed statistically a higher improvements in LDL-C, total cholesterol, HDL-C and 
triglycerides in comparison to pravastatin and simvastatin (5%–15%). Rosuvastatin 
was statistically superior against atorvastatin in LDL-C and total cholesterol, however 
not in HDL-C and triglycerides (p < 0.01). Atorvastatin obtained higher reductions 
in acute myocardial infarctions (AMI), unstable angina, and revascularizations in 
comparison to pravastatin and simvastatin (p < 0.05). Atorvastatin 80 mg showed in 
comparison to pravastatin 40 mg a higher reduction of mayor cardiovascular events 
(OR 0.87; 95%CI 0.77–0.97, p = 0.01), revascularization (OR 0.86; IC95% 0.76–
0.98, p = 0.02) and unstable angina (OR 0.74; 95%CI 0.57–0.95, p = 0.02); neverthe-
less no statistical differences were found for AMI or cardiovascular death. Rosuvastatin 
requires data on cardiovascular events prevention in order to be compare appropri-
ately against atorvastatin. The frequency of adverse events resulted similar among all 
the statins considered in the assessment. CONCLUSIONS: Atorvastatin in comparison 
to pravastatin and simvastatin showed a higher control of dyslipidemia and a better 
reduction of major cardiovascular events, without increasing the frequency of adverse 
events.
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OBJECTIVES: To examine incidence of and the health outcomes associated with 
potential drug-drug interactions (DDIs) between ACE/ARBs and potassium sparing 
diuretics among Medicaid patients. METHODS: A retrospective matched cohort study 
was conducted of beneﬁciaries in the Mississippi Medicaid program from January 
2002 to December 2004. Potential DDIs were deﬁned as medication possession data 
indicating an object drug (ACE/ARB) and a precipitant drug (potassium sparing 
diuretic) were taken with overlapping dates. The ﬁrst day of overlap was designated 
as the DDI index date. A 6-month washout period was used for exposures. Exposed 
patients were matched 1-1 to controls taking ACE/ARBs and assigned the same index 
date. Exact matching was done on sex, race, CHF comorbidity, and cerobrovascular 
disease comorbidity and close matching was done for age (±10) and ﬁrst use date for 
ACE/ARB (±45). Outcomes included hospitalizations and ER visits within 30 days of 
the index date and payments associated with these services. RESULTS: A total of 
68,299 patients were identiﬁed as taking ACE/ARBs during the observation period 
with 5572 (8.4%) exposed to a potential DDI. A total of 5599 exposed patients were 
matched. The effect of DDI exposure on hospitalization and ER visit rates was tested 
using SAS ﬁxed effects logistical regression while controlling for sex, age, race and 
overall Charlson comorbidity index. The point-speciﬁc odds ratio for DDI exposure 
was 1.41 (95% CI = 1.29 − 1.54) for hospitalization and 1.21 (95% CI = 1.11 − 1.31) 
for ER visits. A paired t-test was used to examine differences in Medicaid payments 
during the 30-days after the index date. Total payments were signiﬁcantly higher (p 
< 0.001) for the exposed patients ($2289) than for the control patients ($1,614). 
CONCLUSIONS: Potential ACE/ARB DDIs were a signiﬁcant problem among the 
Mississippi Medicaid patients and during the study period; potentially contributing 
more than $3.7M in additional health care costs.
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OBJECTIVES: Adverse events –Aes—due to medication errors are numerous. One 
type of error is the combination of substances with a known unwanted pharmacologi-
cal interaction. In the years 2001 to 2006 a total of 39521 AEs with ICD10 codes 
indicating drugs as reason where documented in Austrias hospitals. There is no report-
ing system or documentation for adverse events in ambulatory care. So the rate of 
AEs in the outpatient setting is unknown. One of the main projects in Austrias e-health 
roadmap is an e-medication system. Due to the foreseeable costs an estimation and 
calculation of potential beneﬁts is mandatory. METHODS: We use reimbursement 
data of the Austrian social insurance companies covering the years 2006 and 2007. 
The domains included are pharmaceutical reimbursement, reimbursement of outpa-
tient medical services, hospital reimbursement data and sick leave data. We focus on 
interactions between the following pharmaceutical groups: 1. ATC code C10AA—
statins, 2. ATC code N5BA—benzodiacepins, 3. ATC code J01FA makrolide antibiot-
ics and 4. ATC code C01BD amiodarone. RESULTS: The main question to answer 
is the prevalence and incidence of such interaction patterns. This will lead to a descrip-
tion of the epidemiology of potential AEs which can at least be qualiﬁed as medical 
errors. The second question is the frequency of clinical relevant interactions. A clinical 
(and economic) relevance is ascertained, if the interaction needs medical treatment. 
The detection of outcomes of an interaction is the main challenge. CONCLUSIONS: 
The extent to which an e-medication system can improve patient safety can be esti-
